Morgan Stanley Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $95 price target.
August 04, 2023 | 7:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Ultragenyx Pharmaceutical and maintained a $95 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. An Overweight rating suggests that the analyst believes the stock will outperform its industry in the near term. Maintaining a $95 price target indicates that the analyst sees potential for the stock's price to reach this level. This could lead to increased investor interest in RARE and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100